Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Advancements in Personalized Medicine: Integrating Genomic Insights and Therapeutic Strategies
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advancements in Personalized Medicine: Integrating Genomic Insights and Therapeutic Strategies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 6819

Special Issue Editor

Dr. Mariarosaria Boccellino

E-Mail
Guest Editor
Department Life Sciences, Health and Health Professions, Link University, 00165 Rome, Italy
Interests: cerebral hypoxia; prostate cancer; malignant teratoma of the mediastinum; aminoaciduria; antioxidant activity; obesity; molecular biology; translational medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue delves into the forefront of personalized medicine, wherein the fusion of genomic insights with cutting-edge bio-molecular features will pave the way for innovative therapeutic strategies. Emphasizing the integration of genomic data, we invite contributions that spotlight the intricate molecular mechanisms underpinning personalized treatment approaches. From explorations of biomarkers to in-depth analyses of bio-molecular pathways, this issue aims to bridge the gap between genomic discoveries and their practical application in tailoring therapeutic interventions. We welcome submissions that showcase the synergy between clinical insights and rigorous bio-molecular experiments, encouraging more comprehensive understanding of personalized medicine’s evolving landscape.

Dr. Mariarosaria Boccellino
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • genomic insights
  • therapeutic strategies
  • molecular profiling
  • precision medicine
  • molecular targets
  • precision oncology
  • genomic biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 3165 KiB  
Article
Genomic Characterization of Preclinical Prostate Cancer Cell Line Models
by Erica L. Beatson, Emily N. Risdon, Giulia C. Napoli, Douglas K. Price, Cindy H. Chau and William D. Figg
Int. J. Mol. Sci. 2024, 25(11), 6111; https://doi.org/10.3390/ijms25116111 - 1 Jun 2024
Viewed by 2053
Abstract
As we move into the era of precision medicine, the growing relevance of genetic alterations to prostate cancer (PCa) development and treatment demonstrates the importance of characterizing preclinical models at the genomic level. Our study investigated the genomic characterization of eight PCa cell [...] Read more.
As we move into the era of precision medicine, the growing relevance of genetic alterations to prostate cancer (PCa) development and treatment demonstrates the importance of characterizing preclinical models at the genomic level. Our study investigated the genomic characterization of eight PCa cell lines to understand which models are clinically relevant. We designed a custom AmpliSeq DNA gene panel that encompassed key molecular pathways targeting AR signaling, apoptosis, DNA damage repair, and PI3K/AKT/PTEN, in addition to tumor suppressor genes. We examined the relationship between cell line genomic alterations and therapeutic response. In addition, using DepMap’s Celligner tool, we identified which preclinical models are most representative of specific prostate cancer patient populations on cBioPortal. These data will help investigators understand the genetic differences in preclinical models of PCa and determine which ones are relevant for use in their translational research. Full article
(This article belongs to the Special Issue Advancements in Personalized Medicine: Integrating Genomic Insights and Therapeutic Strategies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 915 KiB  
Review
Gene Therapy for Inherited Liver Disease: To Add or to Edit
by Yue Chen, Niek P. van Til and Piter J. Bosma
Int. J. Mol. Sci. 2024, 25(23), 12514; https://doi.org/10.3390/ijms252312514 - 21 Nov 2024
Cited by 1 | Viewed by 1337
Abstract
Patients suffering from an inherited severe liver disorder require lifelong treatment to prevent premature death. Until recently, the only curative treatment option was liver transplantation, which requires lifelong immune suppression. Now, liver-directed gene therapy, which is a much less invasive procedure, has become [...] Read more.
Patients suffering from an inherited severe liver disorder require lifelong treatment to prevent premature death. Until recently, the only curative treatment option was liver transplantation, which requires lifelong immune suppression. Now, liver-directed gene therapy, which is a much less invasive procedure, has become a market-approved treatment for hemophilia A and B. This may pave the way for it to become the treatment of choice for many other recessive inherited liver disorders with loss-of-function mutations. Inherited liver disease with toxic-gain-of-function or intrinsic hepatocyte damage may require alternative applications, such as integrating vectors or genome editing technologies, that can provide permanent or specific modification of the genome. We present an overview of currently available gene therapy strategies, i.e., gene supplementation, gene editing, and gene repair investigated in preclinical and clinical studies to treat inherited severe liver disorders. The advantages and limitations of these gene therapy applications are discussed in relation to the underlying disease mechanism. Full article
(This article belongs to the Special Issue Advancements in Personalized Medicine: Integrating Genomic Insights and Therapeutic Strategies)
►▼ Show Figures

Figure 1

13 pages, 1821 KiB  
Review
Epigenetics, Microbiome and Personalized Medicine: Focus on Kidney Disease
by Giuseppe Gigliotti, Rashmi Joshi, Anam Khalid, David Widmer, Mariarosaria Boccellino and Davide Viggiano
Int. J. Mol. Sci. 2024, 25(16), 8592; https://doi.org/10.3390/ijms25168592 - 6 Aug 2024
Cited by 3 | Viewed by 2449
Abstract
Personalized medicine, which involves modifying treatment strategies/drug dosages based on massive laboratory/imaging data, faces large statistical and study design problems. The authors believe that the use of continuous multidimensional data, such as those regarding gut microbiota, or binary multidimensional systems properly transformed into [...] Read more.
Personalized medicine, which involves modifying treatment strategies/drug dosages based on massive laboratory/imaging data, faces large statistical and study design problems. The authors believe that the use of continuous multidimensional data, such as those regarding gut microbiota, or binary multidimensional systems properly transformed into a continuous variable, such as the epigenetic clock, offer an advantageous scenario for the design of trials of personalized medicine. We will discuss examples focusing on kidney diseases, specifically on IgA nephropathy. While gut dysbiosis can provide a treatment strategy to restore the standard gut microbiota using probiotics, transforming epigenetic omics data into epigenetic clocks offers a promising tool for personalized acute and chronic kidney disease care. Epigenetic clocks involve a complex transformation of DNA methylome data into estimated biological age. These clocks can identify people at high risk of developing kidney problems even before symptoms appear. Some of the effects of both the epigenetic clock and microbiota on kidney diseases seem to be mediated by endothelial dysfunction. These “big data” (epigenetic clocks and microbiota) can help tailor treatment plans by pinpointing patients likely to experience rapid declines or those who might not need overly aggressive therapies. Full article
(This article belongs to the Special Issue Advancements in Personalized Medicine: Integrating Genomic Insights and Therapeutic Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop